## PATENT COOPERATION TREATY

# **PCT**

# TRANSLATION INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference  JP004-PCT	FOR FURTHER ACTION	See Form PCT/IPEA/416			
International application No.	International filing date (day/month	/year) Priority date (day/month/year)			
PCT/JP2004/017182	18.11.2004	21.11.2003			
International Patent Classification (IPC) or nati		•			
C12N15/09, C12Q1/68,	G01N33/50, G01N3	3/15			
Applicant					
BIO-THINK TANK CO., I	IID.				
This report is the international preling under Article 35 and transmitted to the second control of the se		ed by this International Preliminary Examining Authority			
2. This REPORT consists of a total of	6 shee	s, including this cover sheet.			
3. This report is also accompanied by A					
a. (sent to the applicant and	to the International Bureau) a total c	f sheets, as follows:			
		have been amended and are the basis for this report and/or			
sheets containing red Instructions).	ctifications authorized by this Author	ity (see Rule 70.16 and Section 607 of the Administrative			
the disclosure in the	sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplemental				
Box.	D				
b (sent to the International )	Bureau only) a total of (indicate type	and number of electronic carrier(s))			
		, containing a sequence listing and/or tables			
	related thereto, in computer readable form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the Administrative Instructions).				
4. This report contains indications relati	ng to the following items:				
Box No. I Basis of the	report				
Box No. II Priority					
Box No. III Non-establi	shment of opinion with regard to nov	elty, inventive step and industrial applicability			
Box No. IV Lack of unit	y of invention				
Box No. VI Certain doc	Box No. VI Certain documents cited				
Box No. VII Certain defe	ects in the international application				
Box No. VIII Certain obse	ervations on the international applica	ion			
Date of submission of the demand	Date of comp	letion of this report			
		•			
Name and mailing address of the IPEA/JP	Authorized o	ficer			
Facsimile No.	Telephone No	0.			

International application No.

PCT/JP2004/017182

Box	No. I		Basis of the report		
1.		_	d to the language, this report is based on the internation	nal application in the language in which	it was filed, unless otherwise
			report is based on translations from the original langua h is the language of a translation furnished for the purpo		,
		$\sqcup$	international search (Rule 12.3 and 23.1(b))		
		$\sqcup$	publication of the international application (Rule 12.4)		
		Ш	international preliminary examination (Rule 55.2 and/o	or 55.3)	
2.	rece		d to the <b>elements</b> of the international application, this in Confice in response to an invitation under Article 14 are :		
	$\boxtimes$	the in	ternational application as originally filed/furnished		
	Ш	the de	escription:		
		pages			as originally filed/furnished
		pages	*	received by this Authority on	
		pages	*	received by this Authority on	
		the cl	aims:		
		nos.			_ as originally filed/furnished
		nos.*		as amended (together with a	any statement) under Article 19
		nos.*		received by this Authority on	
		nos.*		received by this Authority on	
		the dr	rawings:		
		sheets			as originally filed/furnished
		sheets			_
		sheets		received by this Authority on	
	$\boxtimes$		uence listing and/or any related table(s) – see Suppleme		_
_		_		chial Box Relating to Sequence Listing.	
3.	ш		amendments have resulted in the cancellation of:		
			the description, pages		
			the claims, nos.		
		H	the sequence listing (specify):		
	_	ш			
4.	Ш		report has been established as if (some of) the amend have been considered to go beyond the disclosure as fil		
		님	the description, pages		
		님	the claims, nos.		
			the drawings, sheets/figs		
			the sequence listing (specify):		
			any table(s) related to sequence listing (specify):		
*	If ite	ет 4 ар	plies, some or all of those sheets may be marked "supe	erseded."	

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement				
1.	Statement			
	Novelty (N)	Claims	1-13	YES
		Claims		NO
	Inventive step (IS)	Claims	_2, 3	YES
		Claims	1, 4-13	NO
	Industrial applicability (IA)	Claims	1-13	YES
		Claims		_ NO

#### 2. Citations and explanations (Rule 70.7)

Document 1: Nucleic Acids Research, Vol. 31, No. 2, 15

January 2003, pages 700 to 707

Document 2: JP 2003-116543 A (Tosoh Corp.), 22 April 2003

Document 3: Science, Vol. 294, 2001, pages 853 to 858

Document 4: Nucleic Acids Research, Vol. 32, No. 3, 09 February 2004, pages 936 to 948

The inventions set forth in claims 1 and 4 to 13 do not involve an inventive step in the light of the inventions disclosed in documents 1 to 3 cited in the international search report.

Document 1 indicates that it is possible to evaluate the RNAi activity of a gene by:

constructing an expression vector wherein a target expression molecule, which contains a target sequence and an expression regulation domain for regulating the expression of the RNA that includes said target sequence, has been bonded to the nucleic acid to be evaluated, which is evaluated in order to determine whether or not said nucleic acid exhibits an RNAi activity against the RNA that includes said target sequence;

introducing said expression vector into a cell; and analyzing the phenotype of the cell.

Box No. V

Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

Meanwhile, document 2 discloses a method for evaluating the toxicity or the like of a substance based on the expression of target RNA within a cell; therein, the substance is supplied to the interior of an expression system capable of expressing the target RNA in order to evaluate whether or not the target cells are transcribed based on whether or not the target RNA is expressed.

Methods for evaluating the RNAi activity of a nucleic acid are well known, as disclosed in document 1, and thus it is considered possible to conceive that RNA interference is one type of toxicity that may be exhibited by the substance to be tested in the evaluation method disclosed in document 2.

Such being the case, it is considered to be easy for a person skilled in the art to conceive of attempting to evaluate the RNA interference characteristics of a substance to be tested by means of the invention disclosed in document 2; likewise, it is also considered to be easy for a person skilled in the art to conceive of employing the nucleic acid from the invention disclosed in document 1 as the substance to be tested in the invention disclosed in document 2.

In addition, the fact that it is necessary to provide a control when carrying out an evaluation is considered to have been well known on the priority date of the present application. Therefore, it is not considered to be especially difficult to apply the abovementioned well-known feature and provide a control when attempting to evaluate the RNA interference characteristics of a substance by means of the invention disclosed in document 2; likewise, it is not considered

International application No.
PCT/JP2004/017182

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

to be especially difficult to configure so that target RNA with a sequence that is not affected by RNA interference is used as a control when evaluating RNA interference by means of the invention disclosed in document 2.

Moreover, it is not considered to be especially difficult to conceive of evaluating miRNA activity, which was known to be one type of RNAi activity on the priority date of the present application (if necessary, refer to document 3), by means of a method for evaluating genes that express an RNAi activity as derived from the inventions disclosed in documents 1 and 2.

International application No.

PCT/JP2004/017182

Supplemental Box Relating to Sequence Listing					
Continuation of Box No. I, item 2:					
1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, this report was established on the basis of:					
a. type of material					
a sequence listing table(s) related to the sequence listing					
b. format of material					
in written format in computer readable form					
c. time of filing/furnishing					
contained in the international application as filed					
filed together with the international application in computer readable form					
furnished subsequently to this Authority for the purposes of search and/or examination					
received by this Authority as an amendment* on					
2. In addition, in the case that more than one version or copy of a sequence listing and/or table(s) relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.					
3. Additional comments:					
* If item 4 in Box No. I applies, the listing and/or table(s) related thereto, which form part of the basis of the report, may be marked "superseded."					